Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study is to confirm the safety of Symbicort® Turbuhaler® 160/4.5 µg 1, 2 or 4 inhalation
b.i.d. over a 52 week treatment period in asthmatic patients who are being treated with IGCS
and long acting β2-agonist (LABA) and/or other anti-asthmatic drugs.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate